Bristol-Myers Unit Settles Over Generic Cancer Drug
Bristol-Myers unit Celgene has reached a settlement with India-based Hetero Labs, marking the final settlement to come out of Celgene's 2017 lawsuit against a raft of generic-drug makers over patents for...To view the full article, register now.
Already a subscriber? Click here to view full article